西班牙专利ES2625527T9 Increased bioavailability of the drug in naltrexone therapy

专利PDF首页>>西班牙专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:

公开号:ES2625527T9
申请号:ES11845186.3T
申请日:2011-12-02
公开日:2018-09-25
发明作者:Shawn Flanagan；Eduardo Dunayevich
申请人:Orexigen Therapeutics Inc；
IPC主号:

专利说明:

5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
DESCRIPTION
Increase in the bioavailability of the drug in naltrexone therapy
[0001] This application claims priority to US Provisional Patent Application Serial No. 6l / 419,395, filed on December 3, 2010.
BACKGROUND OF THE INVENTION
Field of the Invention
[0002] The present invention relates to compositions for use in increasing the bioavailability of the drug in a naltrexone therapy.
Description of the related technique
[0003] Pharmacological therapies that use naltrexone, including in a combination therapy with bupropion, are being investigated for the treatment of a variety of medical conditions, including overweight and obesity, cardiovascular risk factors, insulin resistance, cravings. of food, visceral fat conditions, smoking, and major depression. Despite the potential use of naltrexone in daily or otherwise regular therapies, the prescribing information currently approved for products containing naltrexone does not refer to studies examining the effects of food on pharmacokinetics. In addition, the prescription information currently approved for Wellbutrin SR® characterizes the effects of food on bupropion exposure, but only reports an 11% increase in maximum plasma concentration (Cmax) and a 17% increase in area under the concentration time curve (AUC). As a result, there is no guidance or restriction in the prescription information for naltrexone, alone or in combination with bupropion, with respect to food or nutritional effects. This is illustrated in US 7,375,111 relating to a pharmaceutical composition containing naltrexone and bupropion. Another illustration of the technique is observed in Greenway, FL, et al., J. Clin. "Endocrinology and Metabolism", 94 (12), 2009, pp. 4898-4906, which refers to a composition of immediate release of naltrexone in combination with sustained release bupropion in the induction of weight loss. Another illustration of the technique, Hausenloy, DJ, Clin. 279-285, refers to a combination of a fixed dose of sustained release bupropion and sustained release naltrexone for the treatment of obesity.
SUMMARY OF THE INVENTION
[0004] The effects of unexpected foods have now been identified for drug therapies that use naltrexone. A clinical trial is described that reveals that the administration of naltrexone and bupropion with food unexpectedly increases the bioavailability of each of these drugs, indicating a positive effect on food. For example, the administration of a weight loss treatment comprising naltrexone and bupropion with a high fat content, high-calona diet to an overweight or obese individual improves the Cmax and AUC of each of these drugs, thus improving The effectiveness of weight loss treatment. Although one does not recommend, administer or take a diet high in calones and high in fat along with treatments that typically involve dietary restrictions (for example, treatments for overweight or obesity, cardiovascular risk factors, insulin resistance, food cravings or conditions of visceral fat), the findings described here allow therapies that involve the administration of naltrexone monotherapy or therapies combined with a wide range of foods.
[0005] In view of the observations described herein, there is a need for methods that account for the effects of positive foods associated with naltrexone monotherapy and combination therapies, including methods of increasing the bioavailability of the drug, providing improved therapies, and provide information to individuals regarding these effects.
[0006] In one embodiment, the invention relates to a pharmaceutical composition for use in the treatment of overweight or obesity comprising a sustained release formulation of naltrexone or a pharmaceutically acceptable salt thereof and a sustained release formulation of bupropion. or a pharmaceutically acceptable salt thereof, wherein said composition is administered in combination with food.
[0007] In one aspect, the invention relates to a composition for use according to the claims, wherein naltrexone or a pharmaceutically acceptable salt thereof is in an amount ranging from about 4 mg to about 32 mg per Dfa with the food.
[0008] In any embodiment described herein, the amount of the naltrexone or pharmaceutically acceptable salt thereof is in the range of about 4 mg to about 32 mg per day; The amount of bupropion or pharmaceutically acceptable salt thereof is in the range of
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
about 90 mg to about 360 mg per day; Naltrexone or its pharmaceutically acceptable salt comprises a non-sequestered formulation of naltrexone or a pharmaceutically acceptable salt thereof; at least one of the naltrexone or pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof is in a sustained release formulation; each of the naltrexone or its pharmaceutically acceptable salt and the bupropion or pharmaceutically acceptable salt thereof is in a sustained release formulation; Naltrexone or its pharmaceutically acceptable salt is administered concurrently with bupropion or pharmaceutically acceptable salt thereof; naltrexone or its pharmaceutically acceptable salt is administered before or after bupropion or a pharmaceutically acceptable salt thereof; naltrexone or its pharmaceutically acceptable salt and bupropion or a pharmaceutically acceptable salt thereof are in a single dosage form; the unique dosage form is selected from the group consisting of a pfldora, a tablet and a capsule; Naltrexone or its pharmaceutically acceptable salt and bupropion or pharmaceutically acceptable salt thereof are administered or are suitable for administration one or more times a day; naltrexone or its pharmaceutically acceptable salt and bupropion or its pharmaceutically acceptable salt are administered or are suitable for administration two or more times a day; the weight loss activity of naltrexone or pharmaceutically acceptable salt thereof and bupropion or pharmaceutically acceptable salt thereof is improved compared to the administration of the same amount of any of the two compounds alone; Naltrexone or its pharmaceutically acceptable salt is in a sustained release formulation; Bupropion or its pharmaceutically acceptable salt is in a sustained release formulation; and / or naltrexone or its pharmaceutically acceptable salt and bupropion or pharmaceutically acceptable salt thereof are together in a single dosage form, where the single dosage form comprises approximately 4 mg, 8 mg or 16 mg of naltrexone, or comprises approximately 90 mg or 180 mg of bupropion or pharmaceutically acceptable salt thereof, and where each of the naltrexone or pharmaceutically acceptable salt thereof and bupropion or pharmaceutically acceptable salt thereof is in a sustained release formulation.
[0009] In any embodiment described herein, the bioavailability of naltrexone or pharmaceutically acceptable salt thereof is increased compared to the bioavailability of the same amount of naltrexone or pharmaceutically acceptable salt thereof is administered without food; increasing bioavailability includes the increase in maximum plasma concentration (Cmax) or the extent of absorption (AUC) of naltrexone or pharmaceutically acceptable salt thereof; the increase in bioavailability comprises an increase in Cmax in the range of about 91% to about 271% and an increase of AUC in the range of about 70% to about 107% for naltrexone or pharmaceutically acceptable salt thereof when taken with a meal. In comparison with the same amount of naltrexone or its pharmaceutically acceptable salt taken during a fasting state; The increase in bioavailability comprises approximately a 3.7-fold increase in Cmax and an approximately 2.1-fold increase in AUC for naltrexone or pharmaceutically acceptable salt thereof when taken with a meal compared to the same amount. of naltrexone or pharmaceutically acceptable salt thereof, taken during a fasting state; and / or the increase in bioavailability comprises approximately a 1.9-fold increase in Cmax and an approximately 1.7-fold increase in AUC for naltrexone or pharmaceutically acceptable salt thereof when taken with a meal compared to the same amount of naltrexone or pharmaceutically acceptable salt thereof taken during a fasting state.
[0010] In any embodiment described herein, the composition for use according to the invention also allows the administration of naltrexone or pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof in multiple doses spaced over time, where at least one of the doses spaced over time are administered with food; The method further comprises administering naltrexone or pharmaceutically acceptable salt thereof and bupropion or pharmaceutically acceptable salt thereof in multiple doses spaced in space, where each of the doses spaced in time is administered with food; The method further comprises providing or administering bupropion or a pharmaceutically acceptable salt thereof; Naltrexone or its pharmaceutically acceptable salt is provided or administered in an amount in the range of about 4 mg to 32 mg per day; and / or the pharmaceutically acceptable bupropion or salt thereof is provided or administered in an amount in the range of, or about, 90 mg to 360 mg per day.
[0011] In any embodiment described herein, the food comprises a fat-rich meal; and / or the food comprises a meal selected from the group consisting of a moderate meal in calonas, of moderate fat, or of approximately 575 calonas and fat that represent, or approximately, 23% of the total content of calonas, a meal rich in calonas and in fat, or about 1,000 calones, or about 50% of the total content of calonas, and a meal that falls within a range defined by moderate and moderate fat and high-fat and high-fat foods.
[0012] In any embodiment described herein, the individual is overweight or obese; and / or the individual suffers from obesity or overweight and a therapeutically effective amount of naltrexone or pharmaceutically acceptable salt thereof and bupropion or pharmaceutically acceptable salt thereof is provided or administered to treat obesity or overweight.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
[0013] In any embodiment described herein, naltrexone or a pharmaceutically acceptable salt thereof is administered to the individual in accordance with the instructions described herein; printed information indicates that the increase in bioavailability comprises an increase in the Cmax or AUC of naltrexone or pharmaceutically acceptable salt thereof; printed information indicates an increase in Cmax between, or between approximately, 91% to 271% and an increase in the AUC between, or between approximately, 70% to 107% for naltrexone or pharmaceutically acceptable salt thereof when taken with a food compared to the same amount of naltrexone or its pharmaceutically acceptable salt taken during a fasting state; printed information also indicates that taking naltrexone or a pharmaceutically acceptable salt thereof with food results in an increase in the bioavailability of naltrexone or a pharmaceutically acceptable salt thereof compared to taking the same amount of naltrexone or a pharmaceutically acceptable salt thereof without food;
[0014] In any embodiment described herein, the composition for use in accordance with the
Invention also comprises at least one dosage form comprising bupropion or a salt.
pharmaceutically acceptable thereof; The composition for use according to the invention allows
dosages for several days, where the dosage of naltrexone or pharmaceutically acceptable salt thereof is in the range of, or about, 4 mg to 32 mg per day; Composition for use according to the invention allows dosages for several days, in which the dosage of bupropion or its pharmaceutically acceptable salt is in the range of, or about, 90 mg to 360 mg per day; and / or the composition for use further comprises a container, in which the container comprises at least one dosage form, and where the printed information is associated with the container.
[0015] In any embodiment described herein, the composition for use for naltrexone or
pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof is, or is approximately, 8 mg of naltrexone or a pharmaceutically acceptable salt thereof and is, or is approximately, 90 mg of bupropion or a pharmaceutically acceptable salt. thereof during the first week of treatment; is, or is approximately, 16 mg of naltrexone or a pharmaceutically acceptable salt thereof and is, or is approximately, 180 mg of bupropion or a pharmaceutically acceptable salt thereof during the second week of treatment; is, or is approximately, 24 mg of naltrexone or a salt
pharmaceutically acceptable thereof and is, or is approximately, 270 mg of bupropion or a salt
pharmaceutically acceptable thereof during the third week of treatment; and is, or is approximately, 32 mg of naltrexone or a pharmaceutically acceptable salt thereof and is, or is approximately 360 mg of bupropion or a pharmaceutically acceptable salt thereof for the fourth and any subsequent week of treatment.
[0016] In any embodiment described herein, the naltrexone or pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof are administered as two 8 mg tablets of sustained release naltrexone twice a day and two 90 mg tablets of sustained release of bupropion twice a day.
[0017] In any embodiment described herein, naltrexone or pharmaceutically acceptable salt thereof and bupropion or pharmaceutically acceptable salt thereof are administered for at least 28 weeks; or naltrexone or its pharmaceutically acceptable salt and bupropion or pharmaceutically acceptable salt thereof are administered for at least 56 weeks.
[0018] The invention also allows the use of naltrexone or a pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of overweight or obesity as described in any of the embodiments described in this document.
[0019] The invention allows the use of naltrexone or a pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof in the preparation of a medicament for increasing the bioavailability of the drug in the therapy of naltrexone weight loss. / bupropion combined as described in any of the embodiments disclosed in this document.
[0020] The invention allows the use of naltrexone or a pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof in the preparation of a medicament to provide improved naltrexone therapy for an individual as described in any of the embodiments described in this document.
[0021] The invention allows the use of naltrexone or a pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof in the preparation of a medicament to provide a weight loss regimen to an individual as described in any of the embodiments described in this document.
[0022] The invention allows the use of naltrexone or a pharmaceutically acceptable salt thereof and bupropion.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
or a pharmaceutically acceptable salt thereof in the preparation of a medicament to maximize the effectiveness of a treatment for overweight or obesity as described in any of the embodiments described herein.
[0023] The invention allows the use of naltrexone or a pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof in the preparation of a medicament to improve patient compliance with instructions to take a composition of loss of weight with food as described in any of the embodiments described herein.
[0024] The invention allows the use of naltrexone or a pharmaceutically acceptable salt thereof and bupropion or a pharmaceutically acceptable salt thereof in the preparation of a medicament to provide an FDA-approved weight loss medication as described in any of the embodiments described in this document.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0025] Various embodiments described herein allow methods of increasing the bioavailability of naltrexone and / or bupropion in naltrexone and combined naltrexone / bupropion therapies. The increased bioavailability of naltrexone and / or bupropion can improve a variety of therapies. For example, greater bioavailability may result in a more effective dosage. In some embodiments, a more effective dosage allows a lower dose of naltrexone and / or bupropion to be administered to an individual. In some embodiments, administration of naltrexone and / or bupropion with food may also reduce the frequency and / or severity of adverse effects associated with naltrexone, bupropion or other drugs. In some embodiments, a reduction in side effects results in improved compliance by the patient with a treatment. The administration of naltrexone or combined naltrexone / bupropion therapies with food can also generally improve the consistency of the pharmacokinetics associated with naltrexone or combined naltrexone / bupropion therapies, since the variability tends to be higher when the bioavailability is low. In some embodiments, this improved consistency allows greater dosing safety and improved safety and / or tolerability for naltrexone, bupropion or other drugs.
[0026] The term "bupropion" may be used generally herein to refer to a bupropion-free base, a pharmaceutically acceptable bupropion salt (including anhydrous forms, for example, anhydrous bupropion), a metabolite of bupropion ( for example, hydroxybupropion, threohydrobupropion and erythrohydrobupropion), a bupropion isomer, or mixtures thereof. Reference herein to "bupropion" shall be understood to encompass all of these forms, unless the context clearly indicates otherwise.
[0027] The term "naltrexone" may be used in a general manner herein to refer to a free base of naltrexone, a pharmaceutically acceptable naltrexone salt (including hydrates and anhydrous forms, for example, naltrexone hydrochloride dihydrate and anhydrous naltrexone hydrochloride), a naltrexone metabolite, a naltrexone isomer, or mixtures thereof. The reference in this document to "naltrexone" shall be understood to encompass all of these forms, unless the context clearly indicates otherwise.
[0028] The term "pharmaceutically acceptable salt", as used herein, refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not nullify the biological activity and properties of the compound. Pharmaceutical salts can be obtained by routine experimentation. Non-limiting examples of pharmaceutically acceptable salts include bupropion hydrochloride, radafaxine hydrochloride, naltrexone hydrochloride, and 6-p naltrexol hydrochloride.
[0029] Throughout the present description, when a particular compound is mentioned by name, for example, bupropion or naltrexone, it is understood that the scope of the present disclosure encompasses pharmaceutically acceptable salts, esters, amides, or metabolites of named compound. For example, in any of the embodiments herein, an active metabolite of naltrexone (eg, naltrexol 6-p) may be used in combination with, or instead of, naltrexone. In any of the embodiments of the present invention, an active metabolite of bupropion, including S, S-hydroxybupropion (i.e., radafaxine), may be used in combination with or instead of bupropion.
[0030] The term "sustained release", as used herein, has its ordinary meaning as understood by those skilled in the art and therefore includes, by way of non-limiting example, the controlled release of a drug from a Dosage form over an extended period of time. For example, in some embodiments, sustained release dosage forms are those that have a release rate that is slower than that of a comparable immediate release form, for example, less than 80% of the release rate of a Immediate release dosage form.
[0031] Those skilled in the art will understand that an immediate-release naltrexone formulation suitable for use as a reference standard is the immediate-release naltrexone formulation, widely
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
commercially available as the ReVia® brand of naltrexone hydrochloride, or an equivalent thereof. Those skilled in the art will also understand that an immediate-release bupropion formulation suitable for use as a reference standard is the immediate-release bupropion formulation, widely commercially available as the bupropion WELLBUTRIN® brand, or an equivalent thereof. The United States government regulates the way in which prescription drugs can be labeled and therefore aqrn reference to the REVIA® brand of naltrexone hydrochloride and the WELLBUTRIN® brand of bupropion have well-known, fixed and defined meanings. for those skilled in the art.
[0032] The term "oral dosage form", as used herein, has its ordinary meaning as understood by those skilled in the art and therefore includes, by way of non-limiting example, a formulation of a drug or drugs in a form administrable to a human being, including tablets, tablets, cores, capsules, pills, loose powder, solutions and suspensions.
[0033] The term "food effect", as used herein, refers to a phenomenon that can influence drug absorption after administration. A food effect can be designated as "negative" when absorption decreases or "positive" when absorption increases and manifests as an increase in bioavailability (for example, as reflected in AUC). Food effects may also refer to changes in the maximum concentration (Cmax), or the time to reach the maximum concentration (Tmax), regardless of overall absorption. As a result, some drugs, whether fasting or fed, may be taken preferably to achieve an optimal desired effect. As used herein, the terms "with food" and "fed" may be used interchangeably. As used herein, the terms "without food", "fasting" and "fasting" may be used interchangeably.
[0034] The terms "mitigate" or "mitigation" of weight gain, as used herein, include the prevention or reduction of the amount of weight gain associated, for example, with the administration of a drug or drug. Change in the activity of life. In some embodiments, the mitigation of weight gain is measured relative to the amount of weight gain typically experienced when only one or none of naltrexone or bupropion is administered.
[0035] The term "promotion" of weight loss, as used herein, includes causing weight loss in relation to a baseline weight reference for at least a portion of the treatment period. This includes an individual who initially gains some weight, but during the course of the treatment loses weight in relation to a baseline before starting the treatment, as well as individuals who recover a portion or all the weight that is lost at the end of the treatment period. In a preferred embodiment, at the end of the treatment period, the individual has lost weight in relation to a base line. In a preferred embodiment, the mitigation of weight gain or the promotion of weight loss in a patient administered with naltrexone and bupropion is greater than when neither one nor one of naltrexone or bupropion is administered, and more preferably at least additive effect. or better than additive or synergistic, of the administration of the two compounds.
[0036] The terms "pharmacokinetic profile" or "pharmacokinetics", as used herein, have their ordinary meaning as understood by those skilled in the art and therefore include, by way of non-limiting example, a characteristic of the curve resulting from the plot concentration (for example, blood plasma or serum) of a drug over time, after administration of the drug to a subject. Therefore, a pharmacokinetic profile includes a pharmacokinetic parameter or set of parameters that can be used to characterize the pharmacokinetics of a particular drug or dosage form when administered to a suitable population. Several pharmacokinetic parameters are known to those skilled in the art, including the area under the concentration versus time curve (AUC), the area under the concentration time curve from time zero to the last quantifiable sampling time (AUCo- t), area under the concentration time curve from zero time extrapolated to infinity (AUCo-oo), area under the concentration time curve in the steady state dosing interval or from time zero to twelve hours (AUCo -12) for dosing twice a day, the maximum concentration (for example, blood plasma / serum) after administration (Cmax), and the time to reach the maximum concentration (for example, blood plasma / serum) after of administration (Tmax). AUCiast indicates the area under the blood plasma concentration versus the time curve from the time of administration to the time of the last time point. Pharmacokinetic parameters can be measured in various ways known to those skilled in the art, for example, for single dose or steady state. Differences in one or more of the pharmacokinetic profiles (for example, Cmax) may indicate the pharmacokinetic distinction between two formulations.
[0037] The term "sequestered", as used herein, refers to a medicament that is not substantially released after administration of a dosage form comprising the drug. For example, dosage forms comprising morphine sulfate and naltrexone have been formulated in a manner that greatly reduces the in vivo release of naltrexone after administration of the intact version of the dosage form, for example, as described. in United States Patent Publication No. 2009/0162450.
[0038] Those skilled in the art will understand that pharmacokinetic parameters can be determined by
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
comparison with a reference standard using the methods of chemical tests known and accepted by those skilled in the art, for example, as described in the examples set forth herein. Since the pharmacokinetics of a drug can vary from one patient to another, such clinical trials generally involve multiple patients and appropriate statistical analysis of the resulting data (for example, ANOVA with 90% confidence). Comparisons of pharmacokinetic parameters may be on a dose-adjusted basis, as understood by those skilled in the art.
[0039] Pharmacokinetic profiles can be determined by analyzing a population of patients who have received a treatment of naltrexone alone, or a combined treatment of naltrexone and one or more other drugs (such as bupropion), with food, and comparing them with a comparable patient population that has received the same treatment without food. In some embodiments, the pharmacokinetic properties are measured after a single drug dose, while in others they are measured at steady state. In some embodiments, the pharmacokinetics can be determined by monitoring a concentration profile of plasma naltrexone and / or active naltrexone metabolite (eg, 6p-naltrexol). In some embodiments, pharmacokinetics can be determined by monitoring a plasma bupropion concentration profile and / or active bupropion metabolite (eg, threohydrobupropion).
[0040] An increase in bioavailability can be determined using one or more measures known to one skilled in the art, such as an increase in AUC, Cmax, or Tmax, which can each independently be an increase that is, is approximately, It is at least about 5%, 10%, 20%, 30%, 40%, 50%, 75%, 100%, 125%, 150%, 175%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 600%, 700% or more, or within a range defined by any of two of these values (for example, 5% -500%, 10% -400%, or 20% - 300%), in which the increase is compared to a reference treatment (for example, a fasted state or a different fed state).
[0041] In preferred embodiments, the bioavailability of naltrexone, bupropion, or metabolites thereof falls outside the standard 80% -125% range for bioequivalence. For example, the 90% confidence interval ("CI") for Cmax or AUC for naltrexone may be greater than 125% of the reference treatment (for example, a fasting state or a different feeding state).
[0042] In some embodiments, the individual has a body mass index (BMI) of at least 25 kg / m2. In some embodiments, the individual has a BMI of at least 30 kg / m2. In some embodiments, the individual has a BMI of at least 40 kg / m2. In some embodiments, the individual has a BMI of less than 25 kg / m2, or a BMI of less than 25 kg / m2 is developed during the course of administration of naltrexone and bupropion. In these embodiments, it may be beneficial for health or cosmetic purposes to mitigate the consequent weight gain or promote weight loss, thereby reducing BMI even more. In some embodiments, the individual has been diagnosed by an overweight or obese doctor. In some embodiments, the individual identifies, and even identifies himself, is overweight or obese, or is identified as having been diagnosed as overweight or obese.
[0043] In some embodiments, the promotion of weight loss is measured by a percentage change of a base weight of the base line. In some of these embodiments, the amount of weight loss is at least about 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 15% or more of the initial body weight, or an interval defined by any of the two previous values. In some embodiments, the promotion of weight loss is measured as a reduction in weight gain relative to the amount of weight gain experienced when none or one of naltrexone and bupropion is administered, and the amount of weight gain reduction is, is at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 105% , 110%, 115%, 120%), or more, or an interval defined by any of the two previous values.
[0044] In some embodiments, the mitigation of weight gain is measured by a percentage change of a base weight of the base line. In some of these embodiments, the amount of weight gain is approximately not greater than, is not greater than approximately 0%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4% 5%, 6%, 7%, 8%, 9%, 10% or more of the initial body weight, or an interval defined by either of the two previous values.
[0045] In some embodiments, the dose of naltrexone and / or bupropion is adjusted so that the patient loses weight at a rate of about 3% of the body weight of the base lmea every six months. However, the rate of weight loss for a patient can be adjusted by the attending physician based on the particular needs of the patient.
[0046] In some embodiments, the mitigation of weight gain or the promotion of weight loss occurs by increasing satiety in the individual. In some embodiments, the mitigation of weight gain or promotion of weight loss occurs by suppressing the individual's appetite. In some embodiments, the treatment comprises the establishment of a diet regimen and / or increased activity.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
[0047] In some embodiments, naltrexone or combination therapy, including naltrexone in combination with bupropion, is in an amount sufficient to affect weight loss, reduce a cardiovascular risk factor, increase insulin sensitivity, reduce food cravings, treat a visceral fat condition, mitigate weight gain or promote weight loss during smoking cessation, or provide weight loss therapy in patients with major depression. Examples of such treatment methods are described in US Patent No. 7,375,111 and 7,462,626 .; in U.S. Patent Publication No. 2007/0275970, 2007/0270450, 2007/0117827, 2007/0179168, 2008/0214592, 2007/0128298, and 2007/0129283 .; in US Patent Application No. 12/751970, 61/167486, and 61/293844 .; and in WO 2009/158114, which describes methods of affecting weight loss, reduction of cardiovascular risk factors, increased insulin sensitivity, reducing food cravings, treatment of visceral fat conditions, mitigation of weight gain or promote weight loss during smoking cessation, and provide weight loss therapy in patients with major depression. In some embodiments, the cardiovascular risk factor includes one or more of the following: total cholesterol level, LDL cholesterol level, HDL cholesterol level, triglyceride level, glucose level, and insulin level. In some embodiments, the cardiovascular risk factor includes one or more of the following: total cholesterol level, HDL cholesterol level and triglycerides.
[0048] In some embodiments, the increase in the effectiveness of a weight loss treatment described herein comprises a mussel in an outcome measure. For example, in some embodiments, increasing efficiency increases the amount of weight loss. In some embodiments, the increase in efficacy decreases the frequency or severity of adverse events, including, but not limited to, nausea, constipation, vomiting, dizziness, dry mouth, headache, and insomnia. In some embodiments, the increase in efficacy improves another secondary assessment criterion, including, but not limited to waist circumference, high levels of sensitivity of the C-reactive protein (hs-CRP), triglyceride levels, levels of HDL cholesterol or the ratio of LDL / HDL cholesterol levels. As one skilled in the art will recognize, in some circumstances, it is desirable to decrease waist circumference, hs-CRP levels, triglyceride levels, and the ratio of HDL / LDL cholesterol levels and increase cholesterol levels HDL In some embodiments, the improvement in the outcome measure is, is about, is at least, or is at least about 1, 2, 3, 4, 5, 7, 10, 12, 15, 20 30, 40, 50 , 60,70, 80, 90, or 100%, or within a range defined by two of these values.
[0049] In some embodiments, the amount of weight loss when a composition for use according to the invention is taken with a meal is significantly more than the amount of weight loss when the treatment is taken without food. In some embodiments, the amount of weight loss when the treatment is taken with a high fat meal is significantly more than the amount of weight loss when the treatment is taken without food. In some embodiments, the amount of weight loss when the treatment is taken with a high fat meal during a steady state of a combined naltrexone / bupropion therapy is significantly more than the amount of weight loss when the treatment is taken in the Same conditions without food.
[0050] The exact formulation, route of administration and dosage for naltrexone and naltrexone combination therapies as described herein may be chosen by the individual physician in view of the patient's condition. {See, for example, Fingl et al. 1975, in "The Pharmacological Basis of Therapeutics", Cap. 1 p. one).
[0051] In some embodiments, naltrexone and bupropion are each divided into equal doses and administered more than once per day. In some embodiments, naltrexone and bupropion are each divided into uneven doses and are administered more than once per day. In some embodiments, naltrexone and bupropion are divided into a different number of doses and administered a different number of times per day. In one such embodiment, the dose of one of naltrexone or bupropion is divided, while the dose of the other is not.
[0052] In some embodiments, one or both of naltrexone and bupropion is administered one, two, three, four, or more times per day. One or both compounds may be administered less than once per day, for example once every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days, or every 1 or 2 weeks, or a range defined by any two of the previous values. In some embodiments, the number of administrations per day is constant (for example, once per day). In other embodiments, the number of administrations is variable. The number of administrations may change depending on the effectiveness of the dosage form, the observed side effects, external factors (for example, a change in another medication), or the length of time the dosage form has been administered.
[0053] In some embodiments, the daily dose of naltrexone may vary from about 4 mg to about 32 mg, or about 8 mg to about 32 mg, or about 8 mg to about 16 mg. In some embodiments, the daily dose is about 4 mg, about 8 mg, about 12 mg, about 16 mg, about 32 mg, of naltrexone, or a range defined by any two of the above values. The selection of a particular dose may be based on the patient's weight. The selection of a particular dose may be based on the identity, dose, and / or dosage schedule of another co-administered compound. However, in some embodiments, it may be necessary.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
use dosages outside these intervals. In some embodiments, the daily dose is administered in a single oral dosage form. In some embodiments, the daily dose of naltrexone is the same, and in some embodiments, the daily dose is different.
[0054] In some embodiments, the daily dose of bupropion may vary from about 90 mg to about 360 mg. In some embodiments, the daily dose is about 90 mg, about 180 mg, about 360 mg of bupropion, or a range defined by any two of the above values. The selection of a particular dose may be based on the patient's weight. The selection of a particular dose may be based on the identity, dose and / or dosage schedule of another co-administered compound. However, in some embodiments, it may be necessary to use dosages outside these ranges. In some embodiments, the daily dose is administered in a single oral dosage form. In some embodiments, the daily dose of bupropion is the same, and in some embodiments, the daily dose is different.
[0055] Compositions for use as described herein may be distributed, provided to a patient for self-administration, or administered to an individual. In some embodiments, the combined naltrexone / bupropion therapies include a third compound.
[0056] In some embodiments, naltrexone and / or bupropion are provided or administered as an oral dosage form. In some embodiments, the oral dosage form is in the form of a pfldora, tablet, core, capsule, oblong tablet, loose powder, solution, or suspension. In a preferred embodiment, the oral dosage form is in the form of a pfldora, tablet or capsule. In some embodiments, combined naltrexone / bupropion therapy is provided in a single oral dosage form. In some embodiments, the oral dosage form is in the form of a three-layer tablet as described in US Patent Publication No. 2008/0113026.
[0057] In some embodiments, at least one of naltrexone and bupropion is administered with variable frequency during treatment. In some of these embodiments, the frequency of variation comprises a decrease in frequency over time. For example, one or both of naltrexone and bupropion may be administered initially more than once a day, followed by administration only once a day at a later point in treatment. In some embodiments, the daily dosage of at least one of naltrexone and bupropion is consistent despite the variable frequency of administration. For example, in some embodiments, two tablets of each of naltrexone and bupropion are initially administered twice a day, while four tablets of each of naltrexone and bupropion are administered once a day at a later point in the treatment. . Alternatively, in some embodiments, one or two tablets of each of naltrexone and bupropion are administered at a later point in the treatment, in which one or two tablets have an equivalent total daily dosage as the two tablets initially administered each of naltrexone. and bupropion twice a day.
[0058] In some embodiments in which one or both of naltrexone and bupropion are administered less than once per day in a controlled release or sustained release (SR) formulation, the dose is selected so that the patient receives a daily dose. which is approximately the same as a daily dose described here.
[0059] In some embodiments, naltrexone, alone or in a combination treatment, is not a sequestered form of naltrexone. For example, in some embodiments, naltrexone is in a non-sequestered controlled release formulation. In some embodiments, naltrexone is a non-sequestered sustained release formulation. In preferred embodiments, at least 50% of the naltrexone is released within 24 hours of administration.
[0060] In some embodiments, at least one of naltrexone or bupropion is administered in consistent daily doses throughout the entire treatment period. In some embodiments, at least one of naltrexone or bupropion is administered in daily variable doses during the treatment period. In some of these embodiments, the daily doses comprise daily dosages increasing over time. In some of these embodiments, daily doses comprise the decrease in daily doses over time.
[0061] In some embodiments, naltrexone and bupropion are administered individually. In some embodiments, naltrexone and bupropion are administered in a single pharmaceutical composition comprising naltrexone and bupropion. In some embodiments, at least one of naltrexone or bupropion is in a sustained release or controlled release formulation. For example, sustained release forms of naltrexone are described in United States Patent Publication No. 2007/0281021. In some embodiments, at least one of naltrexone or bupropion is administered with a physiologically acceptable carrier, diluent or excipient, or a combination thereof. Examples of combinations of naltrexone / bupropion, formulations thereof, and methods of administration thereof are described in US Patent Nos. 7,375, 111 and 7,462,626. The techniques for the formulation and administration of the compounds of the present application can be found in "Remingtons Pharmaceutical Sciences", Mack Publishing Co., Easton, PA, 18th edition, 1990.
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
[0062] In some embodiments, naltrexone is administered before bupropion. In some embodiments, naltrexone is administered after bupropion. In some embodiments, naltrexone and bupropion are co-administered. As used herein, joint administration includes administration in a single dosage form, or separate dosage forms that are administered at, or almost at the same time.
[0063] In some embodiments, administration of naltrexone and bupropion is continued for a period of, or about, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48 , or 52 weeks, or of a range defined by any two of the previous values. In some embodiments, the administration of naltrexone and bupropion is continued until the reduction of symptoms of a disease, disorder, or condition is stabilized during a period of, or about, 1, 2, 3, 4, 5, 6 , or more weeks, or a range defined by any two of the previous values. For example, in some embodiments, the administration of a combined naltrexone / bupropion therapy is continued until the mitigation of weight gain or the favoring of weight loss in an individual is stabilized during a period of, or about , 1, 2, 3, 4, 5, 6, or more weeks, or a range defined by any two of the previous values. In some embodiments, the administration of naltrexone or naltrexone and bupropion is continued until the individual no longer needs a treatment.
EXAMPLES
[0064] The following examples illustrate various aspects of the invention.
Example 1: Single dose of naltrexone and bupropion
[0065] A cross-sectional, open-label, single-dose, randomized, three-phase study was conducted to assess the effects of food on plasma pharmacokinetics of sustained naltrexone release ("naltrexone SR") / Sustained release bupropion ("bupropion SR") in three-layer combination tablets. Healthy adult volunteers (n = 18; 15 males, 3 females, mean age = 37 years, range = 21-59 years) were randomized to receive each of three treatments under a cross design with a minimum wash of 14 days between the treatments The treatments consisted of a single dose of either: (1) two tablets of naltrexone SR 8 mg / bupropion SR 90 mg (ie, two "tablets NB 8/90") under fasting conditions; (2) two NB 8/90 tablets administered shortly after a standardized high-fat meal; or (3) two NB 8/90 tablets administered shortly after a moderately standardized high-fat meal. Blood samples for the determination of plasma concentrations for naltrexone, bupropion, and their respective metabolites were measured within 15 minutes before the dose (base line), and at time points of 0.5-120 hours after of the dose.
[0066] A summary of the food effect comparisons in subjects administered with NB 8/90 tablets are also provided in Table 1. Table 2 presents the results of the statistical comparisons between the fed conditions (ie, treatment 3 ) and fasted (i.e. treatment 1). The administration of NB 8/90 tablets under high fat conditions increased the values of naltrexone Cmax and AUC by 271% and 107%, respectively (ie 3.7 times and 2.1 times the value of the condition of fasting, respectively), and increase bupropion Cmax and AUC by 80% and 38%, respectively (ie 1.8 times and 1.4 times the value of fasting condition, respectively), than those observed with the same tablets administered under fasting conditions. The CIs of 90% of the average geometric mean ratios of naltrexone and bupropion Cmax and AUC were not in the range of 80% to 125%. The average Cmax values and apparent terminal tm elimination for naltrexone were similar for naltrexone between feeding and fasting conditions. For bupropion, the median of Tmax was one hour shorter under feeding conditions than fasting conditions; Tm values of apparent terminal elimination were similar at 22.70 and 20.44 h, respectively. This indicates that the food does not decrease the liquidation, but rather increases the absorption and / or decreases the effect of the first step.
[0067] With respect to metabolites, Cmax was increased 52% for O p -naltrexol, 26%) for threohydrobupropion, and 40% for a pharmacologically weighted compound of bupropion metabolites (PAWC, a single total concentration of related active metabolites with bupropion adjusted for relative potency) under conditions of high fat content compared to fasting conditions, and the upper limits of the 90% CIs for the Cmax percentage geometric average ratios of these metabolites were generally above 125%. AUC for all metabolites and PAWC, and Cmax for hydroxybupropion and erythrohydrobupropion were comparable between high fat and fasting conditions, with all 90% CIs within the range of 80% to 125%.
[0068] The administration of NB 8/90 tablets in conjunction with a normalized fat-rich meal resulted in a positive food effect, with naltrexone Cmax and AUC increasing by approximately 300%) and 100%), respectively, and Bupropion Cmax and AUC increases by approximately 80% and 40%, respectively. In addition, the administration of the combination with food reduces adverse events, especially gastrointestinal events such as nausea. Three of the 18 patients in the fasting group experienced an adverse drug-related event (17%), while only one of the 16 patients in the fed group experienced an adverse event (6%).
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
Table 1. Summary of food effect comparisons in subjects administered with NB 8/90 tablets (Average ratios of percentage geometric square mm)
study Analyte Parameter Comparison of the state in avunas Comparison of estimation of high fat or moderate fat [ value)
Moderate fat estimate [ value} High fat estimate [ value)
Example 1: NB- 233 Cmal £ (ng / mL) Naltrexone N / A 370.57% (<. 0001) * N / A
Bupropion 179.74% (<. 0001) *
AUC (j- ^ (ng'hr / mL} Naltrexone 207.01% (<. 0001) *
Bupropion 133.25% (<. 0001) *
study Analyte Parameter Comparison of the state in avunas Comparison of estimation of high fat or moderate fat [ value)
Moderate fat estimate [ value) High fat estimate [ value)
Example 2: NB- 236 Cmal £ (ng / mL) Naltrexone 180.53% (<. 0001) * 191.64% (0.003) * 105.17% # (0.5738)
Bupropion 117.20% (<0034} ’* 127.97% (0.0002) * 109.47% # (0.0724)
AUC (j- | 2 (ng'hr / mL) ' Naltrexone 169.70% (<. 0091) * 169.97% (<. 0001) * 100.20% # (0.9638)
Bupropion 109.70% # (0.0025) * 111.94% (0.0009) * 102.53% # (0.3627)
Example3: NB- 239 Cmal £ (ng / mL) Naltrexone 213 71% (0.0003) * N / A N / A
Bupropion 98.75% # (0.8986)
AUC ^ (ng'hr / mL) Naltrexone 180.23% (0.0043) *
Bupropion 92.60% (0.4020)
Abbreviations: AUC = area under the zero time concentration-time curve until the last quantifiable sample time (0-t) or extrapolated to infinity (0- ™), Ctbk- maximum plasma concetration. Moderate fat = moderate prandial caloric state, moderate fat: high calbric prandial state, high qrasa; N / A not applicable:, # 1C at 90% cavo within the bioequivalence range of 80-125%; * psC.05
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
Table 2. Statistical comparisons of plasma naltrexone and pharmacokinetic bupropion parameters under fed and fasted conditions of Example 1 (n = 18)
PK parameter ^ Arithmetic mean ± SD (% CV) b
NB 8/90 on an empty stomach (reference) NB or fed% MR fed or fasting (90% Cl) =
Naltrexone
Cma * (ng'rnL) 1.14 z 0.704 (61.5%) 4.00 z 2.52 (63.0%) 370.57 (315.66 - 435.02)
"^ max (hr) 2.00 (0.75. 6.00) 2.00 (0.75, 6.00) Not applicable
* 1/2 (Hr) 5.39 Z 2.60 (42.5%) 4.71 Z 2.14 (45.5%) Not applicable
AUC ^ (ng'hr / mL) 7.98 z 4.04 (50.6%) 16.42 z 6.70 (53.0%) 211 50 (193 11-225.81}
AUCq_ ^ (ng'hr / mL) 6.89 z 4.26 (50.7%) 16.65 z 6.70 (52.3%) 207.01 (193.52 -211.44)
Bupropion
Cmai (ng / mL} 161 z 5.21 (32.4%) 293 z 109 (37.2%) 179.74 (159.99 - 201.93)
Tmax (hr} 3.00 (1.60.4.02) 2.00 (1.25.4.00) Not applicable
tV2 (hr) 20.44 z 7.63 (36.9%) 22.70 z 6.62 (30.0%) Not applicable
Bupropion
AUCD_t (ng'hr / mL) 1650.91 Z 549.06 (35.4%) 2179.15 Z 705.46 (32.4%) 139.50 (130.32 - 148.77)
AUCq ^. (ng'hr / mL) 1616.20 z 574.35 (35.6%) 2253.46 z 718.13 (31.9%) 138.25 (129.55 ■ 147.53)
a = Subject 7 Period 1 Treatment B was excluded due to vomiting
b = Tmax is presented as Medium (Minimum, Maximum)
c = Calculation based on in-transformed parameters
Abbreviations: AUC = area under the zero time concentration-time curve until the last quantifiable sample time (0-t) or extrapolated to infinity (0- ~). Cma = maximum plasma concentration; n = number of subjects; NB 8/90 fed = two three-layer tablets of naltrexone SR 8mg / bupropium SR90 mg administered under fed conditions (Test 2. Treatment C): SD = Standard deviation: LS = Sustained release: ti «= t1 / 2, half-life of apparent terminal elimination: T ™ = Time to reach maximum plasma concentration; 90% CI = 90 percent confidence interval; % CV = Percentage coefficient of variation:% ME-Average ratio of geometric least squares.
Example 2: Effect of food on naltrexone and steady state bupropion
[0069] A phase I, open-label study was carried out in the steady state to evaluate the pharmacokinetics in plasma of minor NB feeding and fasting tablets. An extension of the study allowed the evaluation of the effect of food on the pharmacokinetics of NB tablets. The steady state dosage offers the opportunity to observe the accumulation of bupropion and metabolites, and therefore better estimate the magnitude of the expected pharmacokinetic interactions after chronic administration.
[0070] Days 1-31 of the study were devoted to the primary investigation of the pharmacokinetics of metoprolol in the context of the steady state of dosing with NB tablets. Subjects (n = 18) received a 50 mg metoprolol of the IR tablet on Days 1 and 31. NB was intensified by dose every week from a single NB 8/90 tablet per day on Day 3 at a maximum dose of NB 32/360 (two tablets nB 8/90 BID) beginning on day 24. In the clinical setting (days 1-3 and 27-31), standardized meals were provided before dosing and pharmacokinetic sampling. These meals were moderate in fat and caloric content. The subjects were instructed to take study medication with food during the outpatient phase (Days 426) of the study.
[0071] After Day 31, subjects (n = II; 7 men, 4 women; mean age = 34 years; range = 19-45 years) were given the option to participate in a period of treatment extension of 3 days designed to evaluate the effects of food on naltrexone and pharmacokinetics of bupropion. The evaluation was designed to
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
allow comparisons between feeding conditions (either a "moderate" meal, or a high fat content, high calorie flour) and between both feeding conditions and the fasting state. The treatment sequence of the extension study was as follows:
Tomorrow: Half of fasting subjects
Morning; Half of moderate meals of subjects with high-fat meal in the morning: Opposite condition at night: moderate meal 33 breast
Night; moderate food
Dfa 32 Dfa 33 Dov 34
[0072] Pharmacokinetic data of naltrexone and bupropion after a moderate meal were obtained on day 30. Subjects enrolling in the optional extension continued the administration of BID dosing (with moderate meals) until Day 32. On Day 33 , subjects were randomized in an approximate 1: 1 ratio to receive the morning dose of the study medication, either in the fasting state or in the feeding state with a high-fat meal (57%) , high in calonas (910 kcal). The night dose on day 33, the study medication was administered with food ("moderate" food). For day 34, the subjects received their morning dose under the condition opposite to what they received on the morning of day 33. On days 33 and 34, pharmacokinetic samples were collected for naltrexone, bupropion and their respective metabolites before of the dosage and through 12 hours of sampling after the morning dose. For the purposes of studying the effects of food, the comparisons were between pharmacokinetics of day 30 ("moderate" food) and fasting and high-fat food conditions administered on day 33 and day 34.
[0073] A summary of the comparisons of the effect of food on subjects given NB 8/90 tablets also provided in Table 1. Table 3 shows a summary and statistical comparison of pharmacokinetic parameters of naltrexone and steady state bupropion. Under different food conditions. The change in the composition of the food before the morning dose of moderate fat food, moderate food to high fat food, high in calonas, had no effect on values of the parameters of naltrexone Cmax and AUCo-12 and , with geometric mean ratios and CI for the comparison contained within the range of 80-125% bio equivalence. However, the lower limit of the 90% CI for the comparison of Cmin was below the lower 80% limit. Op-naltrexol results were similar to those for naltrexone, with the exception that 90% CIs for Cmin fell within the range of 80-125%.
[0074] The administration of two NB 8/90 tablets after moderate fat meal, moderate meal in calones and after high fat meal, high in calones resulted in, respectively, 81% and 92%, higher naltrexone values Cmax (ie 1.8 times and 1.9 times the value of the fasting condition) and AUCo-12 values 70% higher (for both meals) (that is, 1.7 times the value of the fasting condition) with respect to administration under fasting conditions. The effect on Cmin values was minor and not consistent, with a 10% higher Cmin for moderate fat food, moderate in calones compared to the fasting condition and 12% lower Cmin for high fat food, high meal in calonas against the fasting condition. In contrast to the effects observed with naltrexone, none of the types of food appear to affect exposure parameters op-naltrexol. With the exception of Cmax in the high fat content compared to fasting conditions, which was slightly increased, all parameters and 90% CI fell within the range of 80-125%.
[0075] The change in the composition of food before the morning dose of a moderate fat meal, moderate meal in high-fat calones, high-calona food had no effect on the absorption of bupropion from of two tablets NB 8/90. The average geometric ratios and ICs at 90% for comparisons of bupropion parameters Cmax, Cmin, and Auco-12 after high-fat food, high in calones compared to moderate fat, moderate food in calonas indicate a change of -10% in Cmax, and all parameters were completely contained within the 80-125% bioequivalence range.
[0076] The administration of two NB 8/90 tablets after a meal of moderate fat, moderate meal in calonas and after a meal high in fat, high meal in calonas showed that the meal generally had no effect on the minimum and general exposure to bupropion relative to the administration in the fasting state, with the ratios of the geometric means and the 90% CI for comparisons of both Cmin and AUCo-12 contained within the 80-125% bioequivalence range. Administration with food resulted in bupropion Cmax falling just outside the bioequivalence interval with respect to fasting administration, with the geometric mean ratios (90% CI) of 117% (107.95% - 127, 25%), respectively, for the moderate fat condition, moderate for calones compared to the fasting condition, and 128% (118.72% - 137.95%), respectively, for the high fat condition, of high caloric content compared to fasting conditions. The prandial state had no effect on the metabolites of bupropion or the PAWC, falling all the ratios of geometric means and ICs to 90% within the range of 80-125%.
[0077] In summary, in individuals in a steady-state naltrexone / bupropion therapy, the
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
administration of two NB 8/90 tablets after a moderate fat meal, moderate in calonas or after a high fat meal, high calorie content resulted in substantially higher naltrexone Cmax and AUCo-12 values, and moderately Cmax values older than bupropion, regarding the state of fasting.
Table 3. Summary and statistical analysis of pharmacokinetic parameters of plasma naltrexone and bupropion in the extension study of Example 2 (n = 11)
PK parameter Arithmetic mean ± St) (% CV) a
NB 8 (30 lined up moderate meal Dla 30 NB 8/30 fasting Dla 33 or 34% MR fed or fasting (90% Cl) * 5
Naltrexone
Cmaj <(ng ^ rnL) 2.60 ± 1.02 {39.4%} 1.47 ± 0.710 (48.2%) 180.53 (154.76 -210.61}
2.00 (1.00. 3.00) 0.75 (0.75, 1.50) Not applicable
AUC ^ (ng'hrfmL) 11.74 ± 4.45 (37.9%) 7.07 ± 2.88 (40.8%) 169.70 (155.90-184.73}
Cmin tng ^ L) 0.195 ± 0.105 (53.8%) 0.172 ± 0.0758 (44.0%) 110.04 (89.98- 134.57)
Bupropion
Cma * (ng ^ rnL) 156 ± 52.5 (33.6%) 131 ± 38.2 (29.1%) 117.20 (107.95 - 127.25)
3.00 (1.50.4.00) 1.99 (1.25, 3.00) Not applicable
AUC0_t (ng'hr / mL) 1055.81 ± 263.05 (24.9%) 964.76 + 249.16 (25.8%) 109.70 (104.74-114.89}
Cmin (og ^ tnL) 39.3 ± 9.61 (24.5%) 416 + 10.4 (24.9%) 94.73 (89.52-100.25)
NB 3/90 fed moderate food Dla 30 NB 8''90 fed high fat food Dla 33 or 34 fed or fasting (90% Cl) b
Naltrexone
Cma * (ng ^ L) 2.60 ± 1.02 {39.4%} 2.84 + 1.53 (53.9%) 105.17 (90.15-122.69}
"^" mai: 2.00 (1.00. 3.00) 3.00 (1.25, 6.00) Not applicable
AUCD4 (ng'hrfmL) 11.74 ± 4.45 (37.9%) 11.79 ± 4.68 (39.7%) 100.20 (92.04-109.07)
^ min (ng / tnL) 0.195 ± 0.105 (53.8%) 0.159 * 0.0895 (56.4%) 80.15 (65.54-98.02.)
Bupropion
Cma * (ng'mL) 156 + 52.5 (33.6%) 167 ± 43.4 (26.0%) 109.47 (100.83 - 118.86)
^ "maK 3.00 (1.50,4.00) 3.00 (1.50, 6.00) Not applicable
AUCD4 (ng'hr / mL) 1055.81 ± 263.05 (24.9%) 1077.71 + 244.24 (22.7%) 102.53 (97.90-107.38)
^ min (ng / tnL) 39.3 ± 9.61 (24.5%} 38.8 ± 9.53 (24.6%) 98.51 (93.09-104.24)
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
(continuation)
NB 8/90 fasting day 33 o- 34 NB 8/90 fed high-fat food Bia 33 or 34% MR fed or fasting (90% Cl) b
Naltrexone
Cma * <ngtmL) 1.47 »0.710 (48.2%) 2.84 * 1.53 (53.9%) 191.64 (155.28 - 236.52)
Tm »(hr> 0.75 (0.75,1.50) 3.00 (1.25, 6.00) Not applicable
AUC0_t (ng'hr / mL) 7.07 ± 2.88 (40.8%) 11.79 ± 4.58 (39.7%) 159.97 (150.53 -191.92)
<Wn0MlL) 0.172 ± 0.0758 (44.0%) 0.159 ± 0.0895 (56.4%) 88.39 (59.25-112.80)
Bupropion
Cma * <ngtmL) 131 ± 38.2 (29.1%) 157 = 43.4 (26.0%) 127.97 (118.72 - 137.95)
^ mai: 1.99 (1.25, 3.00) 3.00 (1.50, 6.00) Not applicable
AUC0_t (ng'hr / mL) 954.76 ± 249.15 (25.8%) 1077.71 + 244.24 (22.7%) 111.94 (107.31-116.77)
Cmir> g ^ L> 41.6 ± 10.4 (24.9%) 38.8 ± 9.53 (24.6%) 92.79 (88.12 - 97.70)
3 = T-iec = is presented as Medium [mmimo, maximum)
b ■ Calculated based on untransformed parameters
Abbreviations: AUC = area under the zero-time concentration-time curve until the last quantifiable sample time (0-t) or extrapolated to the in ﬁ nite (0- ™), Cth * = maximum plasma concentration; n = number of subjects; NB 8/90 fed [moderate food) two maltrexone SR8 mg / bupropion SR90mg triple layer tablets administered under rapid conditions; NB 8/90 Alimentation = Dosage of two maltrexone SR 8mg / bupropion SR90mg triple-layer tablets administered under feeding conditions; SD = Standard deviation; SR = Sustained Noberation: ti,> 2 = t1 / 2 apparent elimination of half-life; Tuat = time to reach the maximum plasma concentration; 90% CI = 90 percent of coefficient of interval SCV = percentage of coefficient of variations MR = average ratio of geometric least squares
Example 3: Naltrexone and bupropion with a moderate fat meal, moderate in calonas
[0078] Two cross-label open-label studies were compared to assess the effects of a moderate fat meal, moderate calona meal for fasting status in naltrexone pharmacokinetics and bupropion after a single dose. Healthy adult volunteers in a first single-dose open label cross-study (n = 20) received two NB 8/90 tablets under a fasting condition. Healthy adult volunteers in a second open-dose, single-dose study (n = 18) received two 8/90 NB tablets administered shortly after a moderate fat meal (23%), moderate in calonas (575 kcal) (analogous to dietary conditions in the phase 3 trials for weight loss with a combined naltrexone / bupropion therapy).
[0079] A summary of the food effect comparisons in subjects administered NB 8/90 tablets also provided in Table 1. Table 4 presents the results of the statistical comparisons between the fed conditions (ie, the second study) and fasted (i.e. the first study). Moderate fat food, moderate in calonas increased naltrexone Cmax and AUCo by 114% and 80%), respectively, compared to the fasting condition (ie 2.1 times and 1.8 times the value of the condition of fasting, respectively). Pharmacokinetics of bupropion was not significantly affected by this type of food, with Cmax and AUC somewhat lower in feeding conditions compared to fasting conditions. The effect of the moderate fat meal, moderate in the pharmacokinetics of naltrexone and bupropion was therefore less marked than the effect of the food after a high fat meal, high caloric content under single dose conditions, but it remained statistically significant for naltrexone.
Table 4. Exploratory statistical comparisons of pharmacokinetic parameters of plasma naltrexone and bupropion under fed and fasting conditions of example 3 (population evaluable, n = 18)
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
PK parameter; Arithmetic mean ± SD (% CV) b
NB 3/90 on an empty stomach NB 8/90 fed% MR (90% Cl) c
Naltrexone
cmai (ng / mL} 1.34 ± 0.763 (57.0%) 2.65 * 1.18 (44.5%) 213.71 (156.28 - 292.23)
Tmat Chr> 1.27 (0.75,4.00) 2.00 (0.75, 6.00) Not applicable
* 1/2 5.07 ± 3.87 (75.4%) 3.70 ± 1.85 (50.0%) Not applicable
AUC0_, (ng'hr / mL) 8.30 + 6.41 (77.2%) 13.41 ± 6.93 (51.6%) 184.22 (132.93-255.30)
AUC ^ (ng'hr / mL) 8.55 * 6.46 (75.6%) 13.63 + 7.15 52.4%) 180.23 (130.60 - 248.71)
Bupropion
Cmaj (ng / mL} 156 + 36.0 (23.7%) 154 I 55.4 (35.9%) 98.75 (83.59 ■ 116.65)
Tmat W 2.07 (1.50.4.01) 3.02 (1.00, 6.00) Not applicable
(hr) 19.83 * 3.24 (16.3%) 15.87 ± 2.84 (17.9%) Not applicable
AUCd_, (ng'hr / mL} 1496.01 + 323.04 (21.6%) 1303.75 + 310.06 (23.6%) 91.55 (78.65-106.56)
AUCq ^. (ng'hr / mL) 1574.93 + 346.49 (22.0%) 1384 85 + 330 19 (23.8%) 92.60 (79.41 - 107.97)
a = Sujetol in Study NB239 was excluded due to vomiting. Subject 9 in Study NB237 was excluded due to vomiting
b = Tmax are presented as Medians (Minimum, Maximum)
c = Calculation based on in-transformed parameters
Abbreviations: AUC = area under the concentration curve - time from zero time to the last quantifiable sample time (0-t) or extrapolated to infinity (0- “), = maximum plasma concentration, n = Number of subjects: NB 9/80 fed = Two triple-layer tablets of naltrexone SR 8 mg / bupropion SR 90 mg administered under fasting conditions (Reference treatment D); NB8 / 90 fed = Two triple-layer tablets of naltrexone SR 8 mg / bupropion SR 90mg administered with moderate calorie meal, moderate fat (Reference treatment B); DE = Standard deviation; SR = Sustained release: = t1 / 2, half-life of apparent terminal leimination, Tmax = time to reach maximum plasma concentration; 90% CI = 90% confidence interval; % CV = percentage coefficient of variation; % MR = Average ratio of least squared squares.
Example 4: Study of the effect of naltrexone and bupropion food
[0080] A study was conducted to evaluate the plasma pharmacokinetics of NB tablets under fasting and fed conditions. Treatment groups consist of patients who are instructed to: (1) take a single dose of two NB 8/90 tablets without food; (2) take a single dose of two NB 8/90 tablets with food; or (3) take two NB 8/90 tablets with a food during a steady state NB 8/90 administration. Blood samples are collected for the determination of plasma concentrations for naltrexone, bupropion, and their respective metabolites before the dose (base line) and at designated time points after the dose.
[0081] When NB 8/90 is taken with food, the AUC and Cmax for naltrexone will be significantly increased. When NB 8/90 is taken with food during a steady state NB 8/90 administration, the AUC and Cmax for naltrexone will be significantly increased.

权利要求:
Claims (13)
[1]
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
1. A pharmaceutical composition for use in the treatment of overweight or obesity comprising a sustained release formulation of naltrexone or a pharmaceutically acceptable salt thereof and a sustained release formulation of bupropion or a pharmaceutically acceptable salt thereof, where said composition is administered in combination with food.
[2]
2. The pharmaceutical composition for use according to claim 1, wherein the amount of said bupropion or a pharmaceutically acceptable salt thereof is in the range of about 90 mg to about 360 mg per day, and the amount of naltrexone of Pharmaceutically acceptable salt thereof is in the range of about 4 mg to about 32 mg per day.
[3]
3. The pharmaceutical composition for use according to claim 1, wherein said naltrexone or pharmaceutically acceptable salt thereof comprises a non-sequestered formulation of naltrexone or a pharmaceutically acceptable salt thereof.
[4]
4. The pharmaceutical composition for use according to claim 1, wherein said naltrexone or pharmaceutically acceptable salt thereof is administered simultaneously with bupropion or a pharmaceutically acceptable salt thereof.
[5]
5. The pharmaceutical composition for use according to claim 1, wherein said naltrexone or pharmaceutically acceptable salt thereof is administered before or after bupropion or a pharmaceutically acceptable salt thereof.
[6]
6. The pharmaceutical composition for use according to claim 1, wherein said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or a pharmaceutically acceptable salt thereof are in a single dosage form.
[7]
7. The pharmaceutical composition for use according to any one of the preceding claims, wherein said food comprises a high fat meal.
[8]
8. The pharmaceutical composition for use according to any one of claims 1 to 7, wherein said food comprises a food selected from the group consisting of a moderate meal in calonas, moderate fat meal of about 575 calonas and fat that represents approximately 23% of the total content of calones; a meal high in calonas, rich in fats of about 1,000 calonas and fat that represents approximately 50% of the total caloric content; and a meal that falls within a range defined by said moderate-calorie, moderate-fat meal and said high-calorie, high-fat meal.
[9]
9. The pharmaceutical composition for use according to any one of claims 1 to 8, wherein said food comprises a moderate-fat, moderate-fat meal.
[10]
10. The pharmaceutical composition for use according to any one of the preceding claims, wherein the treatment program for said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or a pharmaceutically acceptable salt thereof is:
approximately 8 mg of said naltrexone or pharmaceutically acceptable salt thereof and approximately 90 mg of said bupropion or a pharmaceutically acceptable salt thereof for the first week of treatment;
approximately 16 mg of said naltrexone or a pharmaceutically acceptable salt thereof and approximately 180 mg of said bupropion or a pharmaceutically acceptable salt thereof for the second week of treatment;
about 24 mg of said naltrexone or a pharmaceutically acceptable salt thereof and about 270 mg of said bupropion or a pharmaceutically acceptable salt thereof for the third week of treatment; Y
approximately 32 mg of said naltrexone or a pharmaceutically acceptable salt thereof and about 360 mg of said bupropion or a pharmaceutically acceptable salt thereof for the fourth and any subsequent weeks of treatment.
[11]
11. The pharmaceutical composition for use according to any one of the preceding claims, wherein said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or a pharmaceutically acceptable salt thereof were administered as two 8 mg naltrexone tablets. Sustained release twice a day and two 90 mg tablets of sustained release bupropion twice a day.
[12]
12. The pharmaceutical composition for use according to any one of the preceding claims, in
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55
60
65
which said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or a pharmaceutically acceptable salt thereof were administered for at least 28 weeks.
[13]
13. The pharmaceutical composition for use according to any one of the preceding claims, wherein said naltrexone or pharmaceutically acceptable salt thereof and said bupropion or a pharmaceutically acceptable salt thereof were administered for at least 56 weeks.

类似技术:

公开号 | 公开日 | 专利标题

US11110074B2|2021-09-07|Methods of improving the pharmacokinetics of doxepin

ES2625527T3|2017-07-19|Increased bioavailability of the drug in naltrexone therapy

ES2749800T3|2020-03-23|Naltrexone Sustained Release Formulation

KR20180051560A|2018-05-16|Co-therapy including cannabis glyphogens and pentamers for the treatment of obesity and obesity-related disorders

Van Kerrebroeck et al.2009|Desmopressin for the treatment of primary nocturnal enuresis

US20190358222A1|2019-11-28|Increasing Drug Bioavailability In Naltrexone Therapy

同族专利:

公开号 | 公开日

KR20200044158A|2020-04-28|

KR20190058702A|2019-05-29|

IL226504A|2021-01-31|

DK2646031T3|2017-05-22|

TWI618536B|2018-03-21|

AR093182A1|2015-05-27|

KR20140035320A|2014-03-21|

KR101984500B1|2019-05-31|

LT2646031T|2017-06-26|

EP3222280A1|2017-09-27|

IL279626D0|2021-03-01|

PL2646031T3|2017-08-31|

RS56014B1|2017-09-29|

SI3222280T1|2021-11-30|

PT3222280T|2021-04-22|

RU2017144631A|2019-02-18|

KR102258043B1|2021-05-28|

PT2646031T|2017-05-25|

PL3222280T3|2021-11-29|

EP2646031B9|2018-01-10|

HUE053831T2|2021-07-28|

HRP20170734T1|2017-08-11|

DK3222280T3|2021-04-19|

US20130245056A1|2013-09-19|

JP2019056004A|2019-04-11|

AU2017204309A1|2017-07-13|

AU2011336304B2|2017-03-30|

EP3884947A1|2021-09-29|

KR20210063473A|2021-06-01|

RU2013127423A|2015-01-10|

JP2013544290A|2013-12-12|

EP2646031B1|2017-02-22|

RS62149B1|2021-08-31|

ES2625527T3|2017-07-19|

CY1118968T1|2018-01-10|

SI2646031T1|2017-07-31|

BR112013013390A2|2016-09-06|

CA2819262A1|2012-06-07|

CL2013001564A1|2014-05-02|

JP6008866B2|2016-10-19|

MX2013006071A|2013-10-01|

TW201304780A|2013-02-01|

EP3222280B1|2021-01-20|

KR102105857B1|2020-05-04|

HUE034393T2|2018-02-28|

JP6456890B2|2019-01-23|

HRP20210618T1|2021-09-17|

EP2646031A1|2013-10-09|

ES2866879T3|2021-10-20|

IL270841D0|2020-01-30|

AU2011336304A1|2013-07-11|

RU2017144631A3|2021-04-13|

JP2016210809A|2016-12-15|

MX356801B|2018-06-13|

EP2646031A4|2014-04-23|

WO2012075459A1|2012-06-07|

KR20180069089A|2018-06-22|

RU2640561C2|2018-01-09|

LT3222280T|2021-05-10|

CN103313711A|2013-09-18|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

DE10129265A1|2001-06-18|2003-01-02|Hf Arzneimittelforsch Gmbh|Active ingredient combination for drug addiction or intoxicant therapy|

US6972291B2|2002-07-02|2005-12-06|Bernstein Richard K|Method for reducing food intake|

EP1772147A2|2003-03-17|2007-04-11|Japan Tobacco, Inc.|Method for increasing the oral bioavailability of S-[2-cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate|

ES2639579T3|2003-04-29|2017-10-27|Orexigen Therapeutics, Inc.|Compositions for affecting weight loss comprising an opioid antagonist and bupropion|

WO2007016108A1|2005-07-27|2007-02-08|Orexigen Therapeutics, Inc.|Compositions for affecting weight loss|

CA2630624C|2005-11-22|2013-08-06|Orexigen Therapeutics, Inc.|Compositions and methods for increasing insulin sensitivity|

WO2007089318A2|2005-11-23|2007-08-09|Orexigen Therapeutics, Inc.|Compositions and methods for reducing food cravings|

EP1954316A1|2005-11-28|2008-08-13|Orexigen Therapeutics, Inc.|Methods of treating anxiety disorders|

US8916195B2|2006-06-05|2014-12-23|Orexigen Therapeutics, Inc.|Sustained release formulation of naltrexone|

EP2034975B8|2006-06-19|2012-05-16|Alpharma Pharmaceuticals, LLC|Pharmaceutical compositions|

KR101264789B1|2006-06-30|2013-05-15|엘지디스플레이 주식회사|An array substrate for in plan switching LCD and method of fabricating of the same|

CA2693992C|2006-07-20|2017-01-31|Somaxon Pharmaceuticals, Inc.|Methods of improving the pharmacokinetics of doxepin|

US8921344B2|2006-11-03|2014-12-30|Salix Pharmaceuticals, Inc.|Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives|

KR20140088619A|2006-11-09|2014-07-10|오렉시젠 세러퓨틱스 인크.|Unit dosage packages|

KR101654176B1|2006-11-09|2016-09-09|오렉시젠 세러퓨틱스 인크.|Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer|

DE102007036076A1|2007-08-01|2009-02-05|Bayer Healthcare Aktiengesellschaft|Dipeptoid Produgs and their use|

WO2009035473A2|2007-09-13|2009-03-19|Sanfilippo Louis C|Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders|

US20110144145A1|2008-05-30|2011-06-16|Orexigen Therapeutics, Inc.|Methods for treating visceral fat conditions|ES2639579T3|2003-04-29|2017-10-27|Orexigen Therapeutics, Inc.|Compositions for affecting weight loss comprising an opioid antagonist and bupropion|

CA2630624C|2005-11-22|2013-08-06|Orexigen Therapeutics, Inc.|Compositions and methods for increasing insulin sensitivity|

WO2007089318A2|2005-11-23|2007-08-09|Orexigen Therapeutics, Inc.|Compositions and methods for reducing food cravings|

WO2011085331A1|2010-01-11|2011-07-14|Orexigen Therapeutics, Inc.|Methods of providing weight loss therapy in patients with major depression|

IN2015DN00042A|2012-06-06|2015-05-22|Orexigen Therapeutics Inc|

EP3253379A4|2015-02-07|2018-10-10|Intas Pharmaceuticals Limited|Pharmaceutical composition for the treatment of obesity|

CA3083850A1|2017-03-28|2019-10-04|LDN Pharma Limited|An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

US41939510P| true| 2010-12-03|2010-12-03|

US419395P|2010-12-03|

PCT/US2011/063177|WO2012075459A1|2010-12-03|2011-12-02|Increasing drug bioavailability in naltrexone therapy|

[返回顶部]